Stemline Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Stemline Therapeutics sits in the top decile of US sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count).
Stemline Therapeutics: 17 sponsored US clinical trials, 6 recruiting.
Stemline Therapeutics sponsors 17 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 8 completed. 2 of these trials are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 2 trials.
Top-decile sponsor footprint
Stemline Therapeutics ranks in the top decile of sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
8 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
17 total, page 1 of 1
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
NCT07226427
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
NCT06456463
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
NCT06638307
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT06492616
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
NCT05563220
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
NCT05386108
ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study
NCT05596409
A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function
NCT06126575
Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT03778931
Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer
NCT03088527
A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors
NCT02667873
Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)
NCT02268253
SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
NCT02661022
SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission
NCT02270463
A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer
NCT02338349
Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
NCT02113982
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
NCT02078648
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 2 |
| Phase 3 | 2 |
What is open in the Stemline Therapeutics pipeline
6 recruiting of 17 indexed (35% open); 8 completed (47%).
Phase mix: 2 late (III/IV) vs 15 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Stemline Therapeutics: open-pipeline peers nationwide
Peers matched on 17 registered trials and 35% open enrollment, not the therapeutic-area sidebar.
Stemline Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 17 trials (± recruiting share)
- Achieve Life Sciences · 17 trials · 0% recruiting
- BioDelivery Sciences International · 17 trials · 6% recruiting
- Chugai Pharmaceutical · 17 trials · 24% recruiting
- ConvaTec · 17 trials · 18% recruiting
Sponsors near 35% open enrollment (± trial volume)
- Trustees of Dartmouth College · 35% recruiting · 31 trials
- Giselle Sholler · 35% recruiting · 20 trials
- Michael J. Fox Foundation for Parkinson's Research · 36% recruiting · 14 trials
- The Hospital for Sick Children · 35% recruiting · 23 trials
Related
What to do with this Stemline Therapeutics page
17 registered trials is a research-attention snapshot, not an endorsement of Stemline Therapeutics or any single study.
- 6 of Stemline Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Stemline Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Stemline Therapeutics pipeline card: 17 registered trials from official public datasets.Report a data error.